Ashwani Verma
Stock Analyst at UBS
(2.17)
# 2,755
Out of 4,884 analysts
71
Total ratings
41.18%
Success rate
-2.26%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $35.64 | +51.52% | 3 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $410 → $385 | $294.49 | +30.73% | 5 | Jun 30, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $17.01 | +35.21% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $28.85 | +45.58% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $68.45 | -10.88% | 1 | Jun 3, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $137 → $152 | $129.11 | +17.73% | 8 | May 6, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $34.66 | +18.29% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $32.16 | +49.25% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $20.95 | +5.01% | 4 | Apr 28, 2025 | |
| CHRS Coherus Oncology | Maintains: Neutral | $1.5 → $1.05 | $0.81 | +29.63% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $109.45 | +63.55% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $34 | $46.15 | -26.33% | 2 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $8.93 | +56.77% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $67.16 | +69.74% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $14.63 | +269.10% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $105.44 | -0.42% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.37 | -23.01% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $90.90 | -92.30% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.32 | +28.76% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.54 | +2,701.64% | 1 | Oct 11, 2022 |
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $35.64
Upside: +51.52%
United Therapeutics
Jun 30, 2025
Maintains: Buy
Price Target: $410 → $385
Current: $294.49
Upside: +30.73%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $17.01
Upside: +35.21%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.85
Upside: +45.58%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $68.45
Upside: -10.88%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $137 → $152
Current: $129.11
Upside: +17.73%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $34.66
Upside: +18.29%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $32.16
Upside: +49.25%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $20.95
Upside: +5.01%
Coherus Oncology
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $0.81
Upside: +29.63%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $109.45
Upside: +63.55%
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $46.15
Upside: -26.33%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $8.93
Upside: +56.77%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $67.16
Upside: +69.74%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $14.63
Upside: +269.10%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $105.44
Upside: -0.42%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.37
Upside: -23.01%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $90.90
Upside: -92.30%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.32
Upside: +28.76%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.54
Upside: +2,701.64%